New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga. More: AZ’ Farxiga shows CV benefit in diabetes patients Source: News
read moreGW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical. More: GW sells priority review voucher for 5m Source: News
read moreIt’s been a tumultuous four years for Olivier Brandicourt at Sanofi, marked by restructuring, cost cuts, an asset swap and two rare disease buyouts. What happens over the next four years is anybody’s guess, but the company’s deciding now who’ll be at
read moreShares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial. More: Setback for Allergy’s birch pollen immunotherapy Source: News
read moreGilead wants you to know a big chunk of CEO John Milligan’s equity pay last year amounts to severance-pay accounting. But that’s just by way of explaining why Milligan, who resigned last July, raked in $26 million for his last
read moreNovo Nordisk has at least four more years to build up its newer diabetes drugs before they’ll have to compete with Teva’s knockoff versions of its own blockbuster GLP-1 Victoza. And it’s hoping to get its oral semaglutide—the first GLP-1
read more© 1994 - 2026 B.M. Pharmaceuticals